Ingrid Hougen1, David Collister1,2, Mathieu Bourrier1, Thomas Ferguson1,2, Laura Hochheim1, Paul Komenda1,2, Claudio Rigatto1,2, Navdeep Tangri3,2. 1. Chronic Disease Innovation Center, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada; and. 2. Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. 3. Chronic Disease Innovation Center, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada; and ntangri@sogh.mb.ca.
Abstract
BACKGROUND AND OBJECTIVES: The safety of intravenous iron dosing in dialysis is uncertain. Higher-dose intravenous iron may be associated with a higher risk of infections, cardiovascular events, hospitalizations, and mortality. This systematic review aimed to determine the safety of higher-dose versus lower-dose intravenous iron, oral iron, or no iron supplementation in adult patients treated with dialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We searched Medline, EMBASE, Cochrane library, and CINAHL from inception to January 6, 2017 for randomized, controlled trials and observational studies comparing higher-dose intravenous iron with lower-dose intravenous iron, oral iron, or no iron in patients treated with dialysis that had all-cause mortality, infection, cardiovascular events, or hospitalizations as outcomes. RESULTS: Of the 2231 eligible studies, seven randomized, controlled trials and 15 observational studies met inclusion criteria. The randomized, controlled trials showed no association between higher-dose intravenous iron (>400 mg/mo for most studies) and mortality (six studies; n=970; pooled relative risk, 0.93; 95% confidence interval, 0.47 to 1.84; follow-up ranging from 35 days to 26 months) or infection (four studies; n=743; relative risk, 1.02; 95% confidence interval, 0.74 to 1.41). The observational studies showed no association between higher-dose intravenous iron (>200 mg/mo for most studies) and mortality (eight studies; n=241,408; hazard ratio, 1.09; 95% confidence interval, 0.98 to 1.21; follow-up ranging from 3 to 24 months), infection (eight studies; n=135,532; pooled hazard ratio, 1.13; 95% confidence interval, 0.99 to 1.28), cardiovascular events (seven studies; n=135,675; hazard ratio, 1.18; 95% confidence interval, 0.90 to 1.56), or hospitalizations (five studies; n=134,324; hazard ratio, 1.08; 95% confidence interval, 0.97 to 1.19). CONCLUSIONS: Higher-dose intravenous iron does not seem to be associated with higher risk of mortality, infection, cardiovascular events, or hospitalizations in adult patients on dialysis. Strength of this finding is limited by small numbers of participants and events in the randomized, controlled trials and statistical heterogeneity in observational studies.
BACKGROUND AND OBJECTIVES: The safety of intravenous iron dosing in dialysis is uncertain. Higher-dose intravenous iron may be associated with a higher risk of infections, cardiovascular events, hospitalizations, and mortality. This systematic review aimed to determine the safety of higher-dose versus lower-dose intravenous iron, oral iron, or no iron supplementation in adult patients treated with dialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We searched Medline, EMBASE, Cochrane library, and CINAHL from inception to January 6, 2017 for randomized, controlled trials and observational studies comparing higher-dose intravenous iron with lower-dose intravenous iron, oral iron, or no iron in patients treated with dialysis that had all-cause mortality, infection, cardiovascular events, or hospitalizations as outcomes. RESULTS: Of the 2231 eligible studies, seven randomized, controlled trials and 15 observational studies met inclusion criteria. The randomized, controlled trials showed no association between higher-dose intravenous iron (>400 mg/mo for most studies) and mortality (six studies; n=970; pooled relative risk, 0.93; 95% confidence interval, 0.47 to 1.84; follow-up ranging from 35 days to 26 months) or infection (four studies; n=743; relative risk, 1.02; 95% confidence interval, 0.74 to 1.41). The observational studies showed no association between higher-dose intravenous iron (>200 mg/mo for most studies) and mortality (eight studies; n=241,408; hazard ratio, 1.09; 95% confidence interval, 0.98 to 1.21; follow-up ranging from 3 to 24 months), infection (eight studies; n=135,532; pooled hazard ratio, 1.13; 95% confidence interval, 0.99 to 1.28), cardiovascular events (seven studies; n=135,675; hazard ratio, 1.18; 95% confidence interval, 0.90 to 1.56), or hospitalizations (five studies; n=134,324; hazard ratio, 1.08; 95% confidence interval, 0.97 to 1.19). CONCLUSIONS: Higher-dose intravenous iron does not seem to be associated with higher risk of mortality, infection, cardiovascular events, or hospitalizations in adult patients on dialysis. Strength of this finding is limited by small numbers of participants and events in the randomized, controlled trials and statistical heterogeneity in observational studies.
Authors: J R Boelaert; R F Daneels; M L Schurgers; E G Matthys; B Z Gordts; H W Van Landuyt Journal: Nephrol Dial Transplant Date: 1990 Impact factor: 5.992
Authors: George R Bailie; Maria Larkina; David A Goodkin; Yun Li; Ronald L Pisoni; Brian Bieber; Nancy Mason; Lin Tong; Francesco Locatelli; Mark R Marshall; Masaki Inaba; Bruce M Robinson Journal: Nephrol Dial Transplant Date: 2013-10 Impact factor: 5.992
Authors: Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto Journal: N Engl J Med Date: 2009-10-30 Impact factor: 91.245
Authors: Richard A Hirth; Marc N Turenne; John R C Wheeler; Tammie A Nahra; Kathryn K Sleeman; Wei Zhang; Joseph A Messana Journal: Am J Kidney Dis Date: 2013-06-13 Impact factor: 8.860
Authors: Harmeet Singh; John Reed; Sylvia Noble; Jose L Cangiano; David B Van Wyck Journal: Clin J Am Soc Nephrol Date: 2006-03-29 Impact factor: 8.237
Authors: Iain C Macdougall; Sunil Bhandari; Claire White; Stefan D Anker; Kenneth Farrington; Philip A Kalra; Patrick B Mark; John J V McMurray; Chante Reid; Michele Robertson; Charles R V Tomson; David C Wheeler; Christopher G Winearls; Ian Ford Journal: J Am Soc Nephrol Date: 2020-04-06 Impact factor: 10.121
Authors: Xiaojuan Li; Stephen R Cole; Abhijit V Kshirsagar; Jason P Fine; Til Stürmer; M Alan Brookhart Journal: Clin J Am Soc Nephrol Date: 2019-04-15 Impact factor: 8.237
Authors: Iain C Macdougall; Claire White; Stefan D Anker; Sunil Bhandari; Kenneth Farrington; Philip A Kalra; John J V McMurray; Heather Murray; Retha Steenkamp; Charles R V Tomson; David C Wheeler; Christopher G Winearls; Ian Ford Journal: Am J Nephrol Date: 2018-10-10 Impact factor: 3.754
Authors: Lucia Del Vecchio; Robert Ekart; Charles J Ferro; Jolanta Malyszko; Patrick B Mark; Alberto Ortiz; Pantelis Sarafidis; Jose M Valdivielso; Francesca Mallamaci Journal: Clin Kidney J Date: 2020-11-26